Thanks BB, I see the linked study within the artic

Thanks BB, I see the linked study within the article. I’ll have to leave it to more intelligent folks than me to address. But I’ll pop out the link and editors summary.

https://www.science.org/doi/10.1126/science.adl4793

Editor’s summary

Cells modified outside of the body and then reintroduced provide an advantage over most small-molecule therapeutics in that cells can be designed to recognize target molecules in specific tissues and then act locally. Two studies now demonstrate advances in cell engineering for treating human disease (see the Perspective by Davila and Brentjens). Reddy et al. engineered human T cells to make a synthetic receptor that recognized overactive T cells such as those causing autoimmune disease and organ rejection. The most effective modified cells tested were ones in which the synthetic receptor initiated a program causing the production of both an anti-inflammatory cytokine and a receptor that acted as sink for a locally produced proinflammatory cytokine. In mouse models, such cells could be designed with logic programs that protect the desired tissues without detrimental systemic immunosuppression. Simic et al. modified T cells to produce a synthetic receptor that recognized an antigen localized to the extracellular matrix of the brain. The synthetic receptor activated a circuit stimulating the production of chimeric antigen receptors that targeted and killed cancer cells in the brain but not those implanted elsewhere in the mouse. A mouse model of neuroinflammatory brain disease could be treated with cells engineered to locally produce an anti-inflammatory cytokine. —L. Bryan Ray